To the Editor-The emergence of totally drug-resistant (TDR) tuberculosis in India and Iran has been recently discussed in the literature [1, 2] . The 15 TDR tuberculosis cases previously described in Iran were cited as resistant to ''all first-line drugs (FLDs) and second-line drugs (SLDs)'' [1, 2] . The 4 Mumbai cases were resistant to all FLDs (isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin) and SLDs tested (ofloxacin, moxifloxacin, kanamycin, amikacin, capreomycin, paraaminosalicylic acid, ethionamide) [1] .
In 2007, we proposed for the first time the acronym XXDR for extremely drugresistant tuberculosis) [3, 4] to define Mycobacterium tuberculosis strains that were resistant to all FLDs and SLDs available, and we described [4] the first 2 cases in Italy. Both strains were resistant to all FLDs and SLDs (fluoroquinolones, ethionamide, amikacin, para-aminosalycilic acid, capreomycin, kanamycin, cycloserine) and to additional drugs (rifabutin, clofazimine, dapsone, claritromycin, thiacetazon); linezolid was not yet available.
The first case, in a patient who died after 422 days in the hospital and 94 months of treatment, was initially mismanaged and was already resistant to most of the available drugs on the patient's admission to a reference center. The second case, in a patient who died 625 days after hospital admission and after 60 months of treatment, was managed suboptimally, with poor adherence to the prescribed regimen, before the patient's admission to a reference center (Table 1) .
After reaching agreement on the definition of multidrug-resistant (MDR) tuberculosis (eg, resistance to at least isoniazid and rifampicin) and extensively drug-resistant (XDR) tuberculosis (eg, MDR tuberculosis with additional resistance to any fluoroquinolone and to $1 injectable SLD, eg, capreomycin, kanamycin, or amikacin), the international community needs to agree on a definition for the step that follows XDR tuberculosis in terms of severity: TDR or XXDR tuberculosis. Which drugs should compose the panel defining this condition? Should it include all the drugs considered by the World Health Organization to be of unknown or not adequately proven efficacy? Should it include other antimicrobials? How [5] , we demonstrated that the internationally agreed-upon XDR tuberculosis definition had both clinical value (outcomes of XDR tuberculosis cases were worse than those of MDR tuberculosi cases) and operational value (development of superresistance to SLDs reveals the programmatic difficulties of ensuring patients' adherence to the prescribed drugs).
The present debate on the new definition has an advocacy taste on top of its scientific interest. Looking at the media messages reported worldwide over the last weeks, we realized that the terms TDR tuberculosis and XXDR tuberculosis were used to generate interest in the average news reader-as well as probably anxiety or panic.
The tuberculosis control community needs clear definitions, which reflect clinical and operational facts and support the laboratory, clinical, and public health efforts to prevent the emergence of drug resistance and to cure the resistant cases we have already produced. 
